ArticleJournal of proteome research2012
Lectin chromatography/mass spectrometry discovery workflow identifies putative biomarkers of aggressive breast cancers.
Article in Journal of proteome research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- Conditional ablation of heparan sulfate expression in stromal fibroblasts promotes tumor growth in vivo.PloS one · 2023Article
- Article
- Comprehensive Transcriptomic Analysis IdentifiesGenes · 2020Article
- The Diverse Contributions of Fucose Linkages in Cancer.Cancers · 2019Review
- Oncolytic Vaccinia Virus ExpressingMarine drugs · 2019Article
- Article
- Identification a novel clinical biomarker in early diagnosis of human non-small cell lung cancer.Glycoconjugate journal · 2019Article
- Ulva pertusa lectin 1 delivery through adenovirus vector affects multiple signaling pathways in cancer cells.Glycoconjugate journal · 2017Article
- Glycoproteins in Claudin-Low Breast Cancer Cell Lines Have a Unique Expression Profile.Journal of proteome research · 2017Article
- Article
- GlycoPep MassList: software to generate massive inclusion lists for glycopeptide analyses.Analytical and bioanalytical chemistry · 2017Article
- Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins.British journal of cancer · 2016Article
- Multiplexed Targeted Mass Spectrometry-Based Assays for the Quantification of N-Linked Glycosite-Containing Peptides in Serum.Analytical chemistry · 2015Article
- A peptide N-terminal protection strategy for comprehensive glycoproteome analysis using hydrazide chemistry based method.Scientific reports · 2015Article
- Mass spectrometry-based analyses showing the effects of secretor and blood group status on salivary N-glycosylation.Clinical proteomics · 2015Article
- Article
- A universal chemical enrichment method for mapping the yeast N-glycoproteome by mass spectrometry (MS).Molecular & cellular proteomics : MCP · 2014Article
- Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma.Molecular & cellular proteomics : MCP · 2014Article
- CD123 targeting oncolytic adenoviruses suppress acute myeloid leukemia cell proliferation in vitro and in vivo.Blood cancer journal · 2014Article
- Systemic alteration of cell-surface and secreted glycoprotein expression in malignant breast cancer cell lines.Glycobiology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 6 institutions in 2 countries.
Funding
Abstract
We used a lectin chromatography/MS-based approach to screen conditioned medium from a panel of luminal (less aggressive) and triple negative (more aggressive) breast cancer cell lines (n=5/subtype). The samples were fractionated using the lectins Aleuria aurantia (AAL) and Sambucus nigra agglutinin (SNA), which recognize fucose and sialic acid, respectively. The bound fractions were enzymatically N-deglycosylated and analyzed by LC-MS/MS. In total, we identified 533 glycoproteins, ∼90% of which were components of the cell surface or extracellular matrix. We observed 1011 glycosites, 100 of which were solely detected in ≥3 triple negative lines. Statistical analyses suggested that a number of these glycosites were triple negative-specific and thus potential biomarkers for this tumor subtype. An analysis of RNaseq data revealed that approximately half of the mRNAs encoding the protein scaffolds that carried potential biomarker glycosites were up-regulated in triple negative vs luminal cell lines, and that a number of genes encoding fucosyl- or sialyltransferases were differentially expressed between the two subtypes, suggesting that alterations in glycosylation may also drive candidate identification. Notably, the glycoproteins from which these putative biomarker candidates were derived are involved in cancer-related processes. Thus, they may represent novel therapeutic targets for this aggressive tumor subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.